LYPHOMED WILL MARKET HOECHST's THIRD GENERATION CEPHALOSPORIN CEFODIZIME
LYPHOMED WILL MARKET HOECHST's THIRD GENERATION CEPHALOSPORIN CEFODIZIME in the U.S. as a brandname product. The exclusive marketing agreement for cefodizime fits into LyphoMed's long term strategy of moving into proprietary Rx product lines from its base in the hospital generics and nutritionals business. Including cefodizime, LyphoMed now has at least six drugs in development that, once approved, will be marketed as branded products. LyphoMed already markets Pentam (pentamadine) for pneumocystis carinii as a branded product. LyphoMed said it will file an NDA "based on extensive German and Japanese clinical data establishing cefodizime's safety and clinical efficacy." In addition, the company plans to conduct a "multi-center Phase III clinical study in the U.S. as a supplement to the NDA." Cefodizime is covered by a U.S. patent expiring in July 1998, LyphoMed says. Hoechst-Roussel already markets a third-generation cephalosporin product in the U.S., Claforan (cefotaxime). In a related announcement, LyphoMed also reported that it had extended its agreement with Medco Research covering Adenocard (adenosine) as an adjuvant in the treatment of brain tumors. The original agreement between the two companies covered use of Adenocard in supraventricular tachycardia only. An early clinical study at Duke University to investigate Adenocard's usefulness in brain tumors "was commenced recently," LypoMed reported.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth